A disintegrin and metalloproteinase 9 (ADAM9)

A disintegrin and metalloproteinase 9 (ADAM9) is a membrane-anchored zinc-dependent metalloprotease that functions as both a proteolytic enzyme and cell adhesion molecule, making it a multifunctional therapeutic target. ADAM9 contains distinct functional domains—a metalloproteinase domain for cleaving extracellular substrates and a disintegrin domain for integrin binding—enabling it to regulate critical cellular processes including migration, invasion, and signal transduction. The protein is aberrantly overexpressed in multiple human cancers, including pancreatic cancer, triple-negative breast cancer, esophageal squamous cell carcinoma, and non-small-cell lung cancer, where it promotes tumor development, metastasis, and aggressive phenotypes through both proteolytic degradation of extracellular matrix components and enhanced cell adhesion to the tumor microenvironment. ADAM9 also participates in non-malignant pathological processes such as inflammation, angiogenesis, and neurodegenerative disease, and genetic mutations in ADAM9 are associated with cone-rod dystrophy. As a therapeutic target, ADAM9 presents opportunities for inhibition via metalloproteinase activity blocking, adhesion domain antagonism, and gene expression modulation through microRNA manipulation or epigenetic regulation. However, its broad tissue distribution and diverse substrate specificity necessitate careful therapeutic design to minimize off-target effects on normal physiological functions while effectively suppressing cancer-promoting activities.

Other names

ADAM metallopeptidase domain 9Meltrin gammaDisintegrin and metalloproteinase domain-containing protein 9MCMP (Metalloproteinase-cysteine rich domains-containing protein)MDC9KIAA0021CORD9 (Cone-Rod Dystrophy 9)ADAM9-L (long isoform)ADAM9-S (short isoform)

Potential therapeutic mechanisms include metalloproteinase inhibition to block the catalytic activity of the metalloproteinase domain and reduce ectodomain shedding and growth factor release; adhesion inhibition by blocking disintegrin domain interactions to reduce cell migration and invasion; gene expression modulation by targeting miRNA pathways (miR-126, miR-489) to downregulate ADAM9 expression; and epigenetic modulation by targeting histone methyltransferases that upregulate ADAM9 in cancer cells.